Bicycle Therapeutics plc
BCYC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35 | $27 | $14 | $12 |
| % Growth | 30.8% | 86.5% | 23.6% | – |
| Cost of Goods Sold | $173 | $156 | $0 | $0 |
| Gross Profit | -$138 | -$130 | $14 | $12 |
| % Margin | -390.3% | -480.1% | 100% | 100% |
| R&D Expenses | $173 | $156 | $82 | $45 |
| G&A Expenses | $71 | $60 | $50 | $32 |
| SG&A Expenses | $71 | $60 | $50 | $32 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$172 | -$156 | $0 | $0 |
| Operating Expenses | $72 | $60 | $131 | $77 |
| Operating Income | -$210 | -$190 | -$117 | -$66 |
| % Margin | -595% | -704.1% | -806.6% | -561% |
| Other Income/Exp. Net | $36 | $11 | $2 | -$3 |
| Pre-Tax Income | -$174 | -$179 | -$114 | -$68 |
| Tax Expense | -$5 | $1 | -$2 | -$2 |
| Net Income | -$169 | -$181 | -$113 | -$67 |
| % Margin | -479.2% | -669.7% | -779.3% | -571.2% |
| EPS | -2.91 | -5.08 | -3.8 | -2.67 |
| % Growth | 42.7% | -33.7% | -42.3% | – |
| EPS Diluted | -2.9 | -5.08 | -3.8 | -2.67 |
| Weighted Avg Shares Out | 58 | 36 | 30 | 25 |
| Weighted Avg Shares Out Dil | 58 | 36 | 30 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $34 | $14 | $6 | $0 |
| Interest Expense | $2 | $3 | $3 | $3 |
| Depreciation & Amortization | $7 | $7 | $4 | $1 |
| EBITDA | -$165 | -$183 | -$107 | -$64 |
| % Margin | -467.4% | -679.9% | -741.3% | -547.9% |